Abstract
Unprecedented progress continues to be made in the treatment strategies for the myelodysplastic syndromes (MDS). This review provides an introduction to DNA methyltransferase inhibitors. These agents include 5-azacytidine (azacitidine; AZA) and 5-aza-2’- deoxycytidine (decitabine; DAC). In particular, AZA was shown for the first time to significantly prolong the life expectancy of high-risk MDS patients in international multicenter clinical studies. The selection of responders and assessment of the long-term efficacy warrant further study.
Keywords: MDS, DNA hypomethylation, epigenetic therapy, DNA methyltransferase inhibitors, azacitidine, decitabine, long-term efficacy, hematopoietic stem cell disorders, solid tumors, cytotoxic
Current Pharmaceutical Design
Title:Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes
Volume: 18 Issue: 22
Author(s): Kaoru Tohyama
Affiliation:
Keywords: MDS, DNA hypomethylation, epigenetic therapy, DNA methyltransferase inhibitors, azacitidine, decitabine, long-term efficacy, hematopoietic stem cell disorders, solid tumors, cytotoxic
Abstract: Unprecedented progress continues to be made in the treatment strategies for the myelodysplastic syndromes (MDS). This review provides an introduction to DNA methyltransferase inhibitors. These agents include 5-azacytidine (azacitidine; AZA) and 5-aza-2’- deoxycytidine (decitabine; DAC). In particular, AZA was shown for the first time to significantly prolong the life expectancy of high-risk MDS patients in international multicenter clinical studies. The selection of responders and assessment of the long-term efficacy warrant further study.
Export Options
About this article
Cite this article as:
Tohyama Kaoru, Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes, Current Pharmaceutical Design 2012; 18 (22) . https://dx.doi.org/10.2174/1381612811209023190
DOI https://dx.doi.org/10.2174/1381612811209023190 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gallium in Cancer Treatment
Current Topics in Medicinal Chemistry Iron Supplementation Therapy in End-Stage Renal Disease Patients on Maintenance Hemodialysis
Cardiovascular & Hematological Disorders-Drug Targets Organosulphur Compounds Induce Apoptosis and Cell Cycle Arrest in Cervical Cancer Cells via Downregulation of HPV E6 and E7 Oncogenes
Anti-Cancer Agents in Medicinal Chemistry Is Going for Cure in CML Targeting Aberrant Glycogen Synthase Kinase 3β?
Current Drug Targets The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology The Mechanistic Links Between Proteasome Activity, Aging and Agerelated Diseases
Current Genomics Pure Red Cell Aplasia Caused by Azathioprine
Cardiovascular & Hematological Disorders-Drug Targets Type II Topoisomerases as Targets for Quinolone Antibacterials Turning Dr. Jekyll into Mr. Hyde
Current Pharmaceutical Design Pharmacogenetics of Cytochrome P450 (CYP) 1A2 and Variability in Psychotropic Drug Response
Current Psychiatry Reviews Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry Nicotinamide Adenine Dinucleotide Based Therapeutics
Current Medicinal Chemistry Contemporary Treatment of Amyloid Heart Disease
Current Pharmaceutical Design Peptides Targeting Estrogen Receptor Alpha-Potential Applications for Breast Cancer Treatment
Current Pharmaceutical Design Monoclonal Antibodies in Clinical Oncology
Anti-Cancer Agents in Medicinal Chemistry The Role of Phenolic Compounds in the Fight against Cancer – A Review
Anti-Cancer Agents in Medicinal Chemistry Older and New Formulations of Cladribine. Pharmacology and Clinical Efficacy in Hematological Malignancies
Recent Patents on Anti-Cancer Drug Discovery Sch-66336 (Sarasar®) and Other Benzocycloheptapyridyl Farnesyl Protein Transferase Inhibitors: Discovery, Biology and Clinical Observations
Current Topics in Medicinal Chemistry Main Anti-tumor Angiogenesis Agents Isolated From Chinese Herbal Medicines
Mini-Reviews in Medicinal Chemistry Editorial [Hot Topic:Epigenetic Mechanisms and Therapeutic Strategies (Guest Editors: Victoria Samanidou and Leda Kovatsi)]
Current Medicinal Chemistry Targeting c-MET/HGF Signaling Pathway in Upper Gastrointestinal Cancers: Rationale and Progress
Current Drug Targets